Critical Challenges to Implementing QbD: A Q&A with FDA - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Critical Challenges to Implementing QbD: A Q&A with FDA
Officials from the US Food and Drug Administration discuss best practices for applying quality-by-design concepts. This article contains bonus online-exclusive material.

Pharmaceutical Technology
Volume 33, Issue 10

Changing the pharma mindset

PharmTech» How long do you expect before QbD and its related tools and concepts become a natural practice in drug manufacturing?

»Moore: Many of the approaches of QbD (e.g., continual improvement) are a change to the traditional approach of putting a validated process in place and not touching it. I think that the pharmaceutical community has already made huge strides in advancing QbD concepts. Five years ago, practically no one had heard of design space, and formalized quality risk-management was rarely done. Today, we see a growing number of manufacturers incorporating these concepts in their day-to-day development practice and manufacturing operation.

PharmTech» One way to break down barriers to QbD implementation is to increase communication between industry and the regulatory authorities. Do you expect FDA to seek more interaction with firms during the review process or inspection process?

»Moore: We have already seen a greater level of interaction in many of the QbD applications, both within and outside of the pilot. As I often mention in my presentations, we encourage companies looking to implement QbD approaches to meet with us prior to their submission. Even though not all the details of the design space will be available yet, we find that an end-of-Phase-II meeting [as Mr. Famulare mentioned above] is a good time to start discussing the proposed approaches. Pre-NDA meetings are a good time to discuss more specifics of the content and format of a QbD application. For legacy products, a meeting can be requested to discuss proposed QbD approaches in a supplemental application.

PharmTech» Does FDA expect to see more communication and interaction between, for example, research and development (R&D) departments and quality-control departments?

»Famulare: Yes, these are really important links for successful implementation of a PQS approach within a company to relay not only information but knowledge from development to manufacturing with quality integrated throughout. This applies whether or not QbD approaches are used in product development and especially important to transmit commercial manufacturing information back to R&D. This will also provide for a more robust change-management system within a company to recognize when change can be made to foster continual improvement or in response to a corrective action/preventive action (CAPA). This is an important tenant of the ICH Q10 change-management system element.

It is also important for the regulator to have systems to transfer knowledge between review and inspection. The OC is developing a system of knowledge transfer to facilitate this communication.

PharmTech» There is an informal practice among industry to avoid providing FDA with too much detail out of fear that more information will lead to more questions, and perhaps more 483s. Can you address how the agency is trying to change this mindset?

»Moore: A discussion point in the FDA 2004 report on pharmaceutical quality was to focus on important, well-summarized information in the application, rather than voluminous raw data. I think quality risk-assessment is a good example of the additional important information in a QbD application. It is a change in mindset for companies to admit that they have risk. Of course, their processes have always had risk, and reviewers have always looked for the risks. Addressing these risks and their control in a formalized manner increases transparency and aids in understanding the firm's assurance of product quality.

PharmTech» Is the agency planning to increase its practical workshops or speaking engagements to help clarify the questions that still exist around QbD concepts and quality systems?

»Famulare: There are [still] questions about the regulatory implications [of ICH Q8, Q9, and Q10] and how to present some of these proposals to the agency and how investigators may look at these proposals. I believe that conferences, papers, and shared learning on good case studies will help answer some of these questions and relieve some of these concerns. Those regulators, including myself, and industry members involved in ICH quality initiatives realize that ICH Q8, Q9, and Q10 are forward-looking and that help is needed for implementation. Hence, the ICH Implementation Working Group (IWG), led by rappateur John Louis Robert, is looking to do that through papers and conferences beginning next year. Papers drafted will have input and guidance from I WG members. Any questions about manufacturing and various approaches to science- and risk-based approaches and CGMP interpretations can be directed to DMPQ. So far, we have looked at proposals for RTRT, PAT, and approaches to validation involving continuous manufacturing and verification.


1. ICH, Q8 (R2) Pharmaceutical Development (Geneva, Aug. 2009).

2. ICH, Q9 Quality Risk Management (Geneva, Nov. 2005).

3. ICH, Q10 Pharmaceutical Quality System (Portand, OR, June 2008).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here